

Abatacept

ACG: A-0453 (AC)

[Link to Codes](#)

MCG Health
Ambulatory Care
30th Edition

This MCG care guideline may overlap CMS guidance located in CMS statutes and regulations that are not currently part of MCG's Medicare Compliance content. For Medicare Advantage beneficiaries, before referring to MCG care guidelines, users should first follow all guidance related to this topic located in CMS National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and other statutes and regulations. Content used in MCG care guidelines may be used to supplement but does not replace, modify, or supersede existing Medicare regulations or applicable NCDs or LCDs.

- Clinical Indications
- Evidence Summary
 - Background
 - Criteria
 - Inconclusive or Non-Supportive Evidence
 - Rationale
 - Related CMS Coverage Guidance
- References
- Footnotes
- Codes

Clinical Indications

- Abatacept may be indicated when **ALL** of the following are present(1)(2):
 - Appropriate clinical scenario, as indicated by **1 or more** of the following:
 - ☐ Acute graft vs host disease prophylaxis, as indicated by **ALL** of the following(21)(22)(23):[\[1\]](#)
 - Age 2 years or older
 - Administered in combination with calcineurin inhibitor (eg, cyclosporine, tacrolimus) and methotrexate
 - Patient receiving concurrent antiviral prophylaxis for Epstein-Barr virus reactivation
 - Patient undergoing hematopoietic stem cell transplant from matched or 1-allele-mismatched unrelated donor
 - ☐ Juvenile idiopathic arthritis, as indicated by **1 or more** of the following(26)(27)(28)(29):[\[1\]](#)
 - Initial course, as indicated by **ALL** of the following:
 - Appropriate route for patient age, as indicated by **1 or more** of the following:
 - Intravenous, and age 6 years or older
 - Subcutaneous, and age 2 years or older

- Intolerance of or inadequate response to **1 or more** of the following(27):
 - Methotrexate or leflunomide
 - Tumor necrosis factor inhibitor (eg, adalimumab, etanercept)
 - Joint involvement of 5 joints or more
- Subsequent course, as indicated by **ALL** of the following:
 - Appropriate route for patient age, as indicated by **1 or more** of the following:
 - Intravenous, and age 6 years or older
 - Subcutaneous, and age 2 years or older
 - Favorable response to prior administration of abatacept
- ☐ Psoriatic arthritis, as indicated by **1 or more** of the following(36)(37):^[1]
 - Initial course, as indicated by **ALL** of the following:
 - Appropriate route for patient age, as indicated by **1 or more** of the following:
 - Intravenous, and age 18 years or older
 - Subcutaneous, and age 2 years or older
 - Active psoriatic arthritis, as indicated by **ALL** of the following(38)(39)(40)(41):
 - Active disease with one or more tender and swollen joints
 - Inadequate response, intolerance, or contraindication to **1 or more** of the following:
 - Apremilast
 - Conventional synthetic DMARD (eg, methotrexate, sulfasalazine, hydroxychloroquine, leflunomide)
 - Non-tumor necrosis factor inhibitor biologic medication (eg, abatacept, bimekizumab, guselkumab, ixekizumab, risankizumab, secukinumab, ustekinumab)
 - NSAIDs
 - Tumor necrosis factor inhibitor (eg, adalimumab, certolizumab, etanercept, golimumab, infliximab)
 - Subsequent course, as indicated by **ALL** of the following:
 - Appropriate route for patient age, as indicated by **1 or more** of the following:
 - Intravenous, and age 18 years or older
 - Subcutaneous, and age 2 years or older
 - Favorable response to prior administration of abatacept
- ☐ Rheumatoid arthritis, as indicated by **1 or more** of the following(42)(43)(44):^[1]
 - Initial course, as indicated by **ALL** of the following:
 - Age 18 years or older
 - Inadequate response to 3 or more months of treatment with disease-modifying antirheumatic drug, including **1 or more** of the following(42)(43)(68)(69)(70):
 - Hydroxychloroquine
 - Leflunomide
 - Methotrexate
 - Sulfasalazine
 - Tumor necrosis factor inhibitor (eg, adalimumab, certolizumab, etanercept, golimumab, infliximab)(68)(69)(71)
 - Moderate to severe active rheumatoid arthritis,^[A] as indicated by **1 or more** of the following(73)(74):
 - Clinical Disease Activity Index^[B] score greater than 10
 - Disease Activity Score using 28-joint counts (DAS28)^[C] of 3.2 or greater
 - Patient Activity Scale-II^[D] of 3.71 or greater

- Routine Assessment of Patient Index Data 3[E] score of 7 or greater
 - Simplified Disease Activity Index[F] score greater than 11
- Subsequent course, as indicated by **ALL** of the following:
 - Age 18 years or older
 - Favorable response to prior administration of abatacept
- No active infection(2)(42)(75)(76)
- No concurrent treatment with Janus kinase inhibitor or other biologic drug (eg, tumor necrosis factor inhibitor, anakinra)
- No concurrent use of live vaccine during treatment or within 3 months of discontinuing treatment[G](1)
- No untreated latent or active tuberculosis(2)(42)(75)(77)(78)

Evidence Summary

Background

Abatacept functions as an immunologic agent to block costimulation of T cells, reducing their role in the inflammatory response.(1)(3) **(EG 2)**

Criteria

The evidence for the clinical indications found in this guideline includes 60 published peer reviewed articles, 10 specialty society or other evidence-based guidelines, and 3 Cochrane systematic reviews.

For acute graft vs host disease prophylaxis, evidence demonstrates an incomplete assessment of net benefit vs harm; the drug is currently approved by a federal regulatory agency. **(RG A3)** A phase II trial evaluating abatacept for acute graft vs host disease prophylaxis after hematopoietic stem cell transplant included 2 arms: a randomized double-blind arm including 142 patients with matched donors comparing treatment with a calcineurin inhibitor plus methotrexate with and without concurrent abatacept, and an open-label arm including 43 patients with 1-allele-mismatched donors treated with combination calcineurin inhibitor, methotrexate, and abatacept compared with a historical control cohort. At 100 days post transplant, patients who received abatacept had lower rates of acute graft vs host disease compared with patients who did not: in the double-blind arm, 6.8% and 14.8% of patients receiving abatacept and placebo, respectively; in the open-label arm, 2.3% and 30.2% in the abatacept and historical control groups, respectively.(24) **(EG 2)** An international specialty society guideline states that there is insufficient evidence to make a recommendation regarding the use of abatacept for prophylaxis of acute graft vs host disease.(25) **(EG 2)**

For juvenile idiopathic arthritis, evidence demonstrates at least moderate certainty of at least moderate net benefit. **(RG A1)** Systematic reviews and health technology assessments have found evidence from clinical trials that abatacept demonstrated effectiveness in reducing signs and symptoms of moderate to severe polyarticular juvenile idiopathic arthritis in patients who had failed treatment with disease-modifying antirheumatic drugs and tumor necrosis factor inhibitors.(26)(30)(31)(32) **(EG 1)** A phase III single-arm study of 219 pediatric patients with juvenile idiopathic arthritis who had failed treatment with at least one disease-modifying antirheumatic drug evaluated treatment with subcutaneous abatacept in 2 age cohorts (age 6 to 17 years and age 2 to 5 years). A 30% improvement in JIA-American College of Rheumatology response criteria (JIA-ACR30) was seen at 4 months in 83% and 89% of patients, respectively; at 24 months, the response was seen in 58% and 100% of patients, respectively.(33) **(EG 2)** A practice guideline recommends abatacept as a treatment option for patients with juvenile idiopathic arthritis who do not respond to first-line treatment with methotrexate or a tumor necrosis factor inhibitor.(27) **(EG 2)** Long-term extension studies of patients with juvenile idiopathic arthritis suggest continuing efficacy and safety of abatacept for up to at least 7 years.(34) **(EG 2)** A systematic review identified 3 trials that separately studied the effects of adalimumab, etanercept, and abatacept for treatment of juvenile idiopathic arthritis with polyarthritis; through indirect comparisons, the authors stated that all 3 agents seem to be equally efficacious in preventing disease flare after response to treatment.(35) **(EG 1)**

For psoriatic arthritis, evidence demonstrates at least moderate certainty of at least moderate net benefit. **(RG A1)** A multicenter phase III trial randomized 424 patients with active psoriatic arthritis to weekly subcutaneous abatacept or placebo and found, at 24 weeks, that abatacept was associated with more patients

achieving 20% improvement in American College of Rheumatology response criteria (ACR20). However, quality-of-life and disability parameters were not significantly improved, and there was limited improvement in psoriatic lesions.(37) **(EG 1)** A multicenter randomized phase II study of 170 patients with active psoriatic arthritis and active plaque psoriasis with disease duration of at least 3 months that had not adequately responded to disease-modifying antirheumatic drugs compared 3 abatacept dosing regimens to placebo; after 6 months, patients in the 3 treatment arms were all given a monthly dose of abatacept for a 12-month open-label period. Statistically significant improvement in ACR20 was seen in the patients treated with abatacept doses of 3 mg/kg and 10 mg/kg compared with placebo. The authors concluded that abatacept may be a treatment option in patients with active psoriatic arthritis previously treated with disease-modifying antirheumatic drugs and tumor necrosis factor inhibitors.(36) **(EG 1)** A subspecialty practice guideline cites low-quality evidence that abatacept is a second-line or third-line option for treatment of psoriatic arthritis that is unresponsive to oral medications (eg, methotrexate) or tumor necrosis factor inhibitors.(38) **(EG 2)**

For rheumatoid arthritis, evidence demonstrates at least moderate certainty of at least moderate net benefit. **(RG A1)** Systematic reviews of randomized controlled trials and a technology assessment have concluded that abatacept is effective in patients with moderate to severe active disease that has not responded adequately to therapy with disease-modifying antirheumatic drugs, such as methotrexate, or tumor necrosis factor inhibitors.(45)(46)(47)(48) **(EG 1)** Abatacept is also effective in protecting against radiographic progression of joint disease.(49) **(EG 2)** A randomized controlled trial of 351 patients with less than 2 years of symptoms found that, after 12 months, abatacept administered with methotrexate was significantly more effective than methotrexate alone in terms of Disease Activity Score.(50) **(EG 1)** In an extension of this study, 225 patients with low disease activity at 12 months (defined as Disease Activity Score in 28 Joints using C-reactive protein level (DAS28-CRP) score of less than 3.2) entered a 3-month withdrawal period, after which patients with a subsequent disease flare (defined as meeting at least 2 of 3 criteria: DAS28-CRP score of 1.2 or more, a doubling of tender or swollen joints, and investigator judgment of rheumatoid arthritis flare) were eligible for retreatment with combination abatacept and methotrexate; among 172 patients who received retreatment, mean DAS28-CRP scores improved from 5.28 to 2.41, with 76.6% and 62.9% of patients reaching states of low disease activity and remission, respectively.(51) **(EG 2)** A multicenter, phase IIIb, randomized controlled trial of 646 patients reported that abatacept and adalimumab have comparable efficacy, over a period of at least 2 years, in patients with rheumatoid arthritis.(52)(53) **(EG 1)** A phase IIIb randomized controlled trial of 1457 patients with rheumatoid arthritis with inadequate response to methotrexate compared treatment with subcutaneous abatacept (administered weekly) or intravenous abatacept (on day 1, 15, 29, then monthly) and found, at 6 months, no difference between the groups in the number of patients achieving 20%, 50%, and 70% improvement in American College of Rheumatology response criteria (ACR20, ACR50, and ACR70). After the initial 6-month period, 1372 patients continued therapy with weekly subcutaneous abatacept; at 5-year follow-up, clinical efficacy was maintained, and 25.7% of patients had experienced a serious adverse event, with infection being the most common adverse event.(54)(55) **(EG 1)** An open-label randomized controlled trial of 812 patients with treatment-naïve early rheumatoid arthritis (all of whom had moderate to severe disease activity) compared treatment with methotrexate and either active conventional therapy (eg, prednisolone taper, sulfasalazine, hydroxychloroquine with or without glucocorticoid injections in swollen joints), certolizumab, abatacept, or tocilizumab and found, at 48-week follow-up, that treatment with either certolizumab or abatacept was associated with improved adjusted Clinical Disease Activity Index (CDAI) remission rates compared with active conventional therapy.(56) **(EG 1)** Indirect comparisons of abatacept and other biologic agents have reported comparable efficacy.(57)(58)(59)(60)(61) **(EG 1)** Long-term extension studies of patients with rheumatoid arthritis report that abatacept has an acceptable safety profile for continuous use for up to 8 years.(62)(63)(64) **(EG 2)** Concerns exist regarding the potential development of malignancy in patients with inflammatory arthritis (such as rheumatoid arthritis) receiving biologic therapies such as abatacept. However, a meta-analysis of 29,423 patients from 63 randomized controlled trials reported that the use of such biologic therapies for at least 6 months' duration was not significantly associated with an increased risk of malignancy, as compared with other nonbiologic disease-modifying antirheumatic drugs or with placebo.(65) **(EG 1)** An international specialty society states that biologic medications can be used for the treatment of inflammatory arthritis in patients with cancer in remission; however, because the evidence on the safety of abatacept in these patients is still emerging, abatacept should be considered only when other therapeutic options are unavailable.(66)(67) **(EG 2)**

Inconclusive or Non-Supportive Evidence

For inflammatory bowel disease, evidence demonstrates a lack of net benefit; additional research is recommended. **(RG C1)** Results from 4 randomized placebo-controlled trials evaluating the safety and efficacy of abatacept as induction and maintenance therapy in 451 patients with Crohn disease and 490 patients with ulcerative colitis reported that abatacept was not efficacious for the treatment of these conditions.(4) **(EG 1)**

For inflammatory vasculitis (giant cell arteritis, Takayasu arteritis), evidence is insufficient, conflicting, or poor and demonstrates an incomplete assessment of net benefit vs harm; additional research is recommended. **(RG B)** After an initial treatment of 49 patients with newly diagnosed or relapsing giant cell arteritis with a

regimen of abatacept plus prednisone, the 41 patients who achieved remission were randomized to treatment with monthly abatacept maintenance therapy or placebo; at 12-month follow-up, the maintenance abatacept group was associated with a higher relapse-free survival rate and longer median duration of remission. However, the authors noted that the small sample size limited analysis of potential confounding variables in the study, and there are no standardized measures of disease activity.(5) **(EG 1)** Review articles note that, although abatacept looks promising as a therapy for giant cell arteritis, further studies with more patients are needed to confirm its effectiveness for reducing relapse or as a steroid-sparing agent.(6)(7) **(EG 2)** A randomized trial of 26 patients with Takayasu arteritis (all of whom achieved remission after receiving abatacept at day 1, 15, 29, and at week 8) compared maintenance therapy with monthly abatacept or placebo and found, at 12 months, no difference between the groups in relapse-free survival rates or duration of remission.(8) **(EG 1)** A specialty society guideline states that abatacept is not recommended for the treatment of Takayasu arteritis.(9) **(EG 2)**

For Sjogren syndrome, evidence demonstrates a lack of net benefit; additional research is recommended. **(RG C1)** A randomized phase III trial of 187 patients with active moderate to severe Sjogren syndrome compared treatment with either abatacept or placebo and found, at 169 days' follow-up, no difference in European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (ESSDAI) scores between the groups.(10) **(EG 1)** A specialty society guideline states that the evidence is inconclusive as to whether abatacept is efficacious in the treatment of Sjogren disease.(11) **(EG 2)**

For systemic lupus erythematosus, evidence is insufficient, conflicting, or poor and demonstrates an incomplete assessment of net benefit vs harm; additional research is recommended. **(RG B)** A phase II randomized placebo-controlled trial with 175 patients did not meet the primary endpoint of reduction in subsequent disease flares.(12) **(EG 1)** Subsequent trials have been terminated early due to lack of efficacy.(13)(14)(15) **(EG 2)** Lack of efficacy was also noted in studies of patients with lupus nephritis.(16)(17) **(EG 2)**

For systemic sclerosis, evidence is insufficient, conflicting, or poor and demonstrates an incomplete assessment of net benefit vs harm; additional research is recommended. **(RG B)** A phase II randomized trial of 88 patients with diffuse cutaneous systemic sclerosis compared treatment with abatacept or placebo and found, at 12-month follow-up, no difference in modified Rodnan skin thickness scores between the groups; further randomized trials were recommended.(18) **(EG 1)** International specialty society guidelines do not endorse abatacept for treatment of patients with systemic sclerosis.(19)(20) **(EG 2)**

Rationale

Use of this MCG care guideline helps the clinician determine if a particular treatment, medication, or service might be appropriate for a specific patient, taking into account their unique health complexities.

Use of these evidence-based clinical criteria to support decision making benefits the patient by identifying patient-specific complex clinical factors and conditions, promoting personalized treatment. Utilizing evidence-based clinical criteria promotes patient safety by helping ensure that potential patient benefits outweigh the risks. In addition, the use of evidence-based guidelines can increase consistency in treatment thresholds, leading to less variation in care and promoting equitable treatment among patients.

Related CMS Coverage Guidance

This guideline supplements but does not replace, modify, or supersede existing Medicare regulations or applicable National Coverage Determinations (NCDs) or Local Coverage Determinations (LCDs).

Code of Federal Regulations (CFR): 42 CFR 419.22(79); 42 CFR 422.101(80)

Internet-Only Manual (IOM) Citations: CMS IOM Publication 100-02, Medicare Benefit Policy Manual, Chapter 14 - Medical Devices(81); CMS IOM Publication 100-02, Medicare Benefit Policy Manual, Chapter 15 - Covered Medical and Other Health Services(82); CMS IOM Publication 100-02, Medicare Benefit Policy Manual, Chapter 16 - General Exclusions from Coverage(83)

References

1. Orencia (abatacept) for injection, for intravenous use and for subcutaneous use. Physician Prescribing Information [Internet] Bristol-Myers Squibb Company. 2024 May Accessed at: <https://www.orencia.com/>. [created 2005; accessed 2025 Nov 10] [Context Link 1, 2, 3, 4]
2. Furst DE, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. *Annals of the Rheumatic Diseases* 2013;72 Suppl 2:ii2-ii34. DOI: 10.1136/annrheumdis-2013-203348. [Context Link 1, 2, 3] View abstract...
3. Abatacept Resubmission (Orencia - Bristol-Myers Squibb) Indication: Rheumatoid arthritis. CEDAC Final Recommendation [Internet] Canadian Agency for Drugs and Technologies in Health. 2013 Jul Accessed at: <https://www.cadth.ca/>. [created 2012; accessed 2025 Sep 08] [Context Link 1]
4. Sandborn WJ, et al. Abatacept for Crohn's disease and ulcerative colitis. *Gastroenterology* 2012;143(1):62-69.e4. DOI: 10.1053/j.gastro.2012.04.010. [Context Link 1] View abstract...
5. Langford CA, et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. *Arthritis & Rheumatology* (Hoboken, N.J.) 2017;69(4):837-845. DOI: 10.1002/art.40044. [Context Link 1] View abstract...
6. Gonzalez-Gay MA, Pina T, Prieto-Pena D, Calderon-Goercke M, Blanco R, Castaneda S. The role of biologics in the treatment of giant cell arteritis. *Expert Opinion on Biological Therapy* 2019;19(1):65-72. DOI: 10.1080/14712598.2019.1556256. [Context Link 1] View abstract...
7. Nepal D, Putman M, Unizony S. Giant cell arteritis and polymyalgia rheumatica: treatment approaches and new targets. *Rheumatic Diseases Clinics of North America* 2023;49(3):505-521. DOI: 10.1016/j.rdc.2023.03.005. [Context Link 1] View abstract...
8. Langford CA, et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of Takayasu arteritis. *Arthritis & Rheumatology* (Hoboken, N.J.) 2017;69(4):846-853. DOI: 10.1002/art.40037. [Context Link 1] View abstract...
9. Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of giant cell arteritis and Takayasu arteritis. *Arthritis & Rheumatology* (Hoboken, N.J.) 2021;73(8):1349-1365. DOI: 10.1002/art.41774. (Reaffirmed 2025 Jul) [Context Link 1] View abstract...
10. Baer AN, et al. Efficacy and safety of abatacept in active primary Sjogren's syndrome: results of a phase III, randomised, placebo-controlled trial. *Annals of the Rheumatic Diseases* 2020;80(3):339-348. DOI: 10.1136/annrheumdis-2020-218599. [Context Link 1] View abstract...
11. Price EJ, et al. British Society for Rheumatology guideline on management of adult and juvenile onset Sjogren disease. *Rheumatology* 2024;Online. DOI: 10.1093/rheumatology/keae152. [Context Link 1] View abstract...
12. Merrill JT, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. *Arthritis and Rheumatism* 2010;62(10):3077-87. DOI: 10.1002/art.27601. [Context Link 1] View abstract...
13. Ding HJ, Gordon C. New biologic therapy for systemic lupus erythematosus. *Current Opinion in Pharmacology* 2013;13(3):405-12. DOI: 10.1016/j.coph.2013.04.005. [Context Link 1] View abstract...
14. Touma Z, Urowitz MB, Gladman DD. Systemic lupus erythematosus: an update on current pharmacotherapy and future directions. *Expert Opinion on Biological Therapy* 2013;13(5):723-37. DOI: 10.1517/14712598.2013.764411. [Context Link 1] View abstract...
15. Relan M, Vishwanath S, Shen L, Ambrus JL. Update on the use of biologics in lupus. *Current Pharmaceutical Biotechnology* 2014;15(6):516-20. [Context Link 1] View abstract...
16. Rovin BH, Parikh SV. Lupus nephritis: the evolving role of novel therapeutics. *American Journal of Kidney Diseases* 2014;63(4):677-90. DOI: 10.1053/j.ajkd.2013.11.023. [Context Link 1] View abstract...
17. ACCESS Trial Group. Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study. *Arthritis & Rheumatology* (Hoboken, N.J.) 2014;66(11):3096-104. DOI: 10.1002/art.38790. [Context Link 1] View abstract...
18. Khanna D, et al. Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase II investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial. *Arthritis & Rheumatology* (Hoboken, N.J.) 2020;72(1):125-136. DOI: 10.1002/art.41055. [Context Link 1] View abstract...

19. Del Galdo F, et al. EULAR recommendations for the treatment of systemic sclerosis: 2023 update. *Annals of the Rheumatic Diseases* 2024;Online. DOI: 10.1136/ard-2024-226430. (Reaffirmed 2025 Jul) [Context Link 1] View abstract...
20. Denton CP, et al. The 2024 British Society for Rheumatology guideline for management of systemic sclerosis. *Rheumatology* 2024;Online. DOI: 10.1093/rheumatology/keae394. [Context Link 1] View abstract...
21. Wolfl M, et al. Current prophylaxis and treatment approaches for acute graft-versus-host disease in haematopoietic stem cell transplantation for children with acute lymphoblastic leukaemia. *Frontiers in Pediatrics* 2021;9:Online. DOI: 10.3389/fped.2021.784377. [Context Link 1] View abstract...
22. Watkins B, Williams KM. Controversies and expectations for the prevention of GVHD: A biological and clinical perspective. *Frontiers in Immunology* 2022;13:Online. DOI: 10.3389/fimmu.2022.1057694. [Context Link 1] View abstract...
23. Ngwube A, Rangarajan H, Shah N. Role of abatacept in the prevention of graft-versus-host disease: current perspectives. *Therapeutic Advances in Hematology* 2023;14:Online. DOI: 10.1177/20406207231152644. [Context Link 1] View abstract...
24. Watkins B, et al. Phase II trial of costimulation blockade with abatacept for prevention of acute GVHD. *Journal of Clinical Oncology* 2021;39(17):1865-1877. DOI: 10.1200/JCO.20.01086. [Context Link 1] View abstract...
25. Penack O, et al. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. *Lancet. Haematology* 2024;11(2):e147-e159. DOI: 10.1016/S2352-3026(23)00342-3. [Context Link 1] View abstract...
26. Abatacept, Adalimumab, Etanercept and Tocilizumab for Treating Juvenile Idiopathic Arthritis. NICE Technology Appraisal Guidance TA373 [Internet] National Institute for Health and Care Excellence. 2015 Dec (NICE Reviewed 2018) Accessed at: <https://www.nice.org.uk/guidance/>. [accessed 2024 Sep 18] [Context Link 1, 2]
27. Ringold S, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. *Arthritis Care & Research* 2019;71(6):717-734. DOI: 10.1002/acr.23870. (Reaffirmed 2025 Mar) [Context Link 1, 2, 3] View abstract...
28. Brunner HI, et al. Abatacept: a review of the treatment of polyarticular-course juvenile idiopathic arthritis. *Paediatric Drugs* 2020;22(6):653-672. DOI: 10.1007/s40272-020-00422-2. [Context Link 1] View abstract...
29. Amarilyo G, et al. Biological agents in polyarticular juvenile idiopathic arthritis: A meta-analysis of randomized withdrawal trials. *Seminars in Arthritis and Rheumatism* 2016;46(3):312-8. DOI: 10.1016/j.semarthrit.2016.07.001. [Context Link 1] View abstract...
30. Kemper AR, Van Mater HA, Coeytaux RR, Williams JW, Sanders GD. Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis. *BMC Pediatrics* 2012;12:29. DOI: 10.1186/1471-2431-12-29. [Context Link 1] View abstract...
31. Kemper AR, et al. Disease-modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA). Comparative Effectiveness Review Number 28. AHRQ Publication No. 11-EHC039-EF [Internet] Agency for Healthcare Quality and Research Effective Health Care Program. 2011 Sep Accessed at: <https://www.effectivehealthcare.ahrq.gov/>. [accessed 2025 Sep 03] [Context Link 1] View abstract...
32. Davies R, Gaynor D, Hyrich KL, Pain CE. Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: A systematic review. *Seminars in Arthritis and Rheumatism* 2017;46(5):584-593. DOI: 10.1016/j.semarthrit.2016.10.008. [Context Link 1] View abstract...
33. Brunner HI, et al. Subcutaneous abatacept in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study. *Arthritis & Rheumatology (Hoboken, N.J.)* 2018;70(7):1144-1154. DOI: 10.1002/art.40466. [Context Link 1] View abstract...
34. Lovell DJ, et al. Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years. *Arthritis & Rheumatology (Hoboken, N.J.)* 2015;67(10):2759-70. DOI: 10.1002/art.39234. [Context Link 1] View abstract...
35. Otten MH, Anink J, Spronk S, van Suijlekom-Smit LW. Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons. *Annals of the Rheumatic Diseases* 2013;72(11):1806-12. DOI: 10.1136/annrheumdis-2012-201991. [Context Link 1] View abstract...
36. Mease P, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. *Arthritis and Rheumatism* 2011;63(4):939-48. DOI: 10.1002/art.30176. [Context Link 1, 2] View abstract...
37. Mease PJ, et al. Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. *Annals of the Rheumatic Diseases* 2017;76(9):1550-8. DOI: 10.1136/annrheumdis-2016-210724. [Context Link 1, 2] View abstract...

38. Singh JA, et al. Special article: 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. *Arthritis & Rheumatology* (Hoboken, N.J.) 2019;71(1):5-32. DOI: 10.1002/art.40726. (Reaffirmed 2025 Jun) [Context Link 1, 2] View abstract...
39. Gossec L, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. *Annals of the Rheumatic Diseases* 2024;Online. DOI: 10.1136/ard-2024-225531. (Reaffirmed 2025 Mar) [Context Link 1] View abstract...
40. Guselkumab for Treating Active Psoriatic Arthritis After Inadequate Response to DMARDs. NICE Technology Appraisal Guidance TA711 [Internet] National Institute for Health and Care Excellence. 2021 Jun Accessed at: <https://www.nice.org.uk/guidance/>. [accessed 2024 Sep 25] [Context Link 1]
41. Mohanakrishnan R, Beier S, Deodhar A. IL-23 inhibition for the treatment of psoriatic arthritis. *Expert Opinion on Biological Therapy* 2022;22(1):59-65. DOI: 10.1080/14712598.2021.1938538. [Context Link 1] View abstract...
42. Smolen JS, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. *Annals of the Rheumatic Diseases* 2023;82(1):3-18. DOI: 10.1136/ard-2022-223356. (Reaffirmed 2025 May) [Context Link 1, 2, 3, 4] View abstract...
43. Fraenkel L, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis Care & Research* 2021;73(7):924-939. DOI: 10.1002/acr.24596. (Reaffirmed 2025 Mar) [Context Link 1, 2] View abstract...
44. Donahue KE, et al. Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update. Comparative Effectiveness Review #211 AHRQ publication no. 18-EHC015-EF [Internet] Agency for Healthcare Research and Quality Effective Health Care Program. 2018 Jul Accessed at: <https://www.effectivehealthcare.ahrq.gov/>. [accessed 2025 Sep 04] DOI: 10.23970/AHRQEPCCER211. [Context Link 1] View abstract...
45. Schiff M, et al. Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study. *Annals of the Rheumatic Diseases* 2011;70(11):2003-7. DOI: 10.1136/annrheumdis-2011-200316. [Context Link 1] View abstract...
46. Adalimumab, Etanercept, Infliximab, Certolizumab Pegol, Golimumab, Tocilizumab and Abatacept for Rheumatoid Arthritis Not Previously Treated with DMARDs or After Conventional DMARDs Only Have Failed. NICE Technology Appraisal Guidance TA375 [Internet] National Institute for Health and Care Excellence. 2016 Jan (NICE reviewed 2019) Accessed at: <https://www.nice.org.uk/guidance/>. [accessed 2024 Sep 19] [Context Link 1]
47. Singh JA, et al. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. *Cochrane Database of Systematic Reviews* 2017, Issue 3. Art. No.: CD012591. DOI: 10.1002/14651858.CD012591. [Context Link 1] View abstract...
48. Singh JA, et al. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. *Cochrane Database of Systematic Reviews* 2017, Issue 5. Art. No.: CD012657. DOI: 10.1002/14651858.CD012657. [Context Link 1] View abstract...
49. Combe B, Lula S, Boone C, Durez P. Effects of biologic disease-modifying anti-rheumatic drugs on the radiographic progression of rheumatoid arthritis: a systematic literature review. *Clinical and Experimental Rheumatology* 2018;36(4):658-667. [Context Link 1] View abstract...
50. Emery P, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. *Annals of the Rheumatic Diseases* 2015;74(1):19-26. DOI: 10.1136/annrheumdis-2014-206106. [Context Link 1] View abstract...
51. Emery P, et al. Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study. *Rheumatic & Musculoskeletal Diseases Open* 2019;5(1):e000840. DOI: 10.1136/rmdopen-2018-000840. [Context Link 1] View abstract...
52. Weinblatt ME, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. *Arthritis and Rheumatism* 2013;65(1):28-38. DOI: 10.1002/art.37711. [Context Link 1] View abstract...
53. Schiff M, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. *Annals of the Rheumatic Diseases* 2014;73(1):86-94. DOI: 10.1136/annrheumdis-2013-203843. [Context Link 1] View abstract...
54. Genovese MC, et al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. *Arthritis and Rheumatism* 2011;63(10):2854-64. DOI: 10.1002/art.30463. [Context Link 1] View abstract...
55. Genovese MC, et al. Longterm safety and efficacy of subcutaneous abatacept in patients with rheumatoid arthritis: 5-year results from a phase IIIb trial. *Journal of Rheumatology* 2019;45(8):1085-1092. DOI: 10.3899/jrheum.170344. [Context Link 1] View abstract...
56. Ostergaard M, et al. Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial. *Annals of the Rheumatic Diseases* 2023;82(10):1286-1295. DOI: 10.1136/ard-2023-224116. [Context Link 1] View

abstract...

57. Gallego-Galisteo M, Villa-Rubio A, Alegre-del Rey E, Marquez-Fernandez E, Ramos-Baez JJ. Indirect comparison of biological treatments in refractory rheumatoid arthritis. *Journal of Clinical Pharmacy and Therapeutics* 2012;37(3):301-7. DOI: 10.1111/j.1365-2710.2011.01292.x. [Context Link 1] View abstract...
58. Guyot P, et al. Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United kingdom. *Journal of Rheumatology* 2012;39(6):1198-206. DOI: 10.3899/jrheum.111345. [Context Link 1] View abstract...
59. Jansen JP, Buckley F, Dejonckheere F, Ogale S. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analysis. *Health and Quality of Life Outcomes* 2014;12:102. DOI: 10.1186/1477-7525-12-102. [Context Link 1] View abstract...
60. Alfonso-Cristancho R, et al. Comparative effectiveness of biologics for the management of rheumatoid arthritis: systematic review and network meta-analysis. *Clinical Rheumatology* 2017;36(1):25-34. DOI: 10.1007/s10067-016-3435-2. [Context Link 1] View abstract...
61. Onishi A, et al. Comparative effectiveness of biological disease-modifying antirheumatic drugs and Janus kinase inhibitor monotherapy in rheumatoid arthritis. *Rheumatology* 2023;Online. DOI: 10.1093/rheumatology/kead620. [Context Link 1] View abstract...
62. Weinblatt ME, et al. Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program. *Journal of Rheumatology* 2013;40(6):787-97. DOI: 10.3899/jrheum.120906. [Context Link 1] View abstract...
63. Khraishi M, Russell A, Olszynski WP. Safety profile of abatacept in rheumatoid arthritis: a review. *Clinical Therapeutics* 2010;32(11):1855-70. DOI: 10.1016/j.clinthera.2010.10.011. [Context Link 1] View abstract...
64. Kremer JM, et al. Longterm safety, efficacy, and inhibition of structural damage progression over 5 years of treatment with abatacept in patients with rheumatoid arthritis in the abatacept in inadequate responders to methotrexate trial. *Journal of Rheumatology* 2014;41(6):1077-87. DOI: 10.3899/jrheum.130263. [Context Link 1] View abstract...
65. Lopez-Olivo MA, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. *Journal of the American Medical Association* 2012;308(9):898-908. DOI: 10.1001/2012.jama.10857. [Context Link 1] View abstract...
66. Sebbag E, et al. 2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer. *Annals of the Rheumatic Diseases* 2024;DOI: 10.1136/ard-2024-225982. [Context Link 1] View abstract...
67. Fautrel B, et al. 2024 update of the recommendations of the French Society of Rheumatology for the diagnosis and management of patients with rheumatoid arthritis. *Joint, Bone, Spine* 2024;91(6):105790. DOI: 10.1016/j.jbspin.2024.105790. [Context Link 1] View abstract...
68. Remy A, Avouac J, Gossec L, Combe B. Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis. *Clinical and Experimental Rheumatology* 2011;29(1):96-103. [Context Link 1, 2] View abstract...
69. Schoels M, Aletaha D, Smolen JS, Wong JB. Comparative effectiveness and safety of biological treatment options after tumour necrosis factor a inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. *Annals of the Rheumatic Diseases* 2012;71(8):1303-8. DOI: 10.1136/annrheumdis-2011-200490. [Context Link 1, 2] View abstract...
70. Kerschbaumer A, et al. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. *Annals of the Rheumatic Diseases* 2020;79(6):744-759. DOI: 10.1136/annrheumdis-2019-216656. [Context Link 1] View abstract...
71. Wells AF, Curtis JR, Betts KA, Douglas K, Du EX, Ganguli A. Systematic literature review and meta-analysis of tumor necrosis factor-alpha experienced rheumatoid arthritis. *Clinical Therapeutics* 2017;39(8):1680-1694.e2. DOI: 10.1016/j.clinthera.2017.06.013. [Context Link 1] View abstract...
72. Anderson J, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. *Arthritis Care & Research* 2012;64(5):640-7. DOI: 10.1002/acr.21649. [Context Link 1] View abstract...
73. England BR, et al. 2019 update of the American College of Rheumatology recommended rheumatoid arthritis disease activity measures. *Arthritis Care & Research* 2019;71(12):1540-1555. DOI: 10.1002/acr.24042. [Context Link 1, 2, 3, 4, 5, 6] View abstract...
74. Buzatu C, Moots RJ. Measuring disease activity and response to treatment in rheumatoid arthritis. *Expert Review of Clinical Immunology* 2019;15(2):135-145. DOI: 10.1080/1744666X.2019.1559050. [Context Link 1] View abstract...

75. Singh JA, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database of Systematic Reviews 2011, (verified by Cochrane 2016 Apr), Issue 2. Art. No.: CD008794. DOI: 10.1002/14651858.CD008794.pub2. [Context Link 1, 2] View abstract...
76. Singh JA, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet 2015;386(9990):258-265. DOI: 10.1016/S0140-6736(14)61704-9. [Context Link 1] View abstract...
77. Bombardier C, et al. Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. Journal of Rheumatology 2012;39(8):1583-1602. DOI: 10.3899/jrheum.120165. (Reaffirmed 2025 Jun) [Context Link 1] View abstract...
78. Hewitt RJ, Francis M, Singanayagam A, Kon OM. Screening tests for tuberculosis before starting biological therapy. British Medical Journal 2015;350:h1060. [Context Link 1] View abstract...
79. Centers for Medicare and Medicaid Services. "Hospital services excluded from payment under the hospital outpatient prospective payment system." 42 CFR 419.22 Washington, DC 2023 Jul [accessed 2025 Jul 22] Accessed at: <https://www.ecfr.gov/>. [Context Link 1]
80. Centers for Medicare and Medicaid Services. "Requirements relating to basic benefits." 42 CFR 422.101 Washington, DC 2025 Jun 03 [accessed 2025 Jul 23] Accessed at: <https://www.ecfr.gov/>. [Context Link 1]
81. Centers for Medicare and Medicaid Services. Medicare Benefit Policy Manual. Chapter 14 - Medical Devices Rev. 198 [Internet] Centers for Medicare and Medicaid Services. 2014 Nov 06 Accessed at: <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/>. [accessed 2025 Sep 09] [Context Link 1]
82. Centers for Medicare and Medicaid Services. Medicare Benefit Policy Manual. Chapter 15 - Covered Medical and Other Health Services Rev. 13108 [Internet] Centers for Medicare and Medicaid Services. 2025 Apr 11 Accessed at: <https://www.cms.gov/manuals/>. [accessed 2025 Sep 09] [Context Link 1]
83. Centers for Medicare and Medicaid Services. Medicare Benefit Policy Manual. Chapter 16 - General Exclusions From Coverage Rev. 198 [Internet] Centers for Medicare and Medicaid Services. 2014 Nov 06 Accessed at: <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/>. [accessed 2025 Sep 09] [Context Link 1]
84. Medicare Coverage Database. [Internet] Centers for Medicare and Medicaid Services. Accessed at: <https://www.cms.gov/medicare-coverage-database/search.aspx?> Updated 2025 [accessed 2025 Oct 23] [Context Link 1]

Footnotes

[A] Rheumatoid arthritis disease activity should be evaluated by a validated tool that assesses disease severity; validated disease activity tools typically include a combination of patient self-assessment, physical examination of joints by a physician, and laboratory assessment of inflammatory response. An expert consensus recommendation supports use of the following instruments: the Clinical Disease Activity Index, the Disease Activity Score using 28-joint counts, the Patient Activity Scale-II, the Routine Assessment of Patient Index Data 3, and the Simplified Disease Activity Index.(72) [A in Context Link 1]

[B] The Clinical Disease Activity Index is a scale from 0 to 76 that uses physician joint count and both patient and physician global score to assess rheumatoid arthritis disease severity. A score of 2.8 or less indicates remission, while a score greater than 2.8 to 10 indicates low disease severity. Moderate disease activity is indicated by a score of greater than 10 to 22, and severe disease activity is indicated by a score of greater than 22.(73) [B in Context Link 1]

[C] The Disease Activity Score using 28-joint counts (DAS28) is a scale from 0 to 9.4 that is calculated by counting affected joints, the patient global score, and either the erythrocyte sedimentation rate or C-reactive protein level. A score of less than 2.6 indicates remission, while a score of 2.6 to less than 3.2 demonstrates low disease activity. Moderate disease activity is indicated by a score of 3.2 to 5.1, and severe disease activity is indicated by a score higher than 5.1.(73) [C in Context Link 1]

[D] The Patient Activity Scale and Patient Activity Scale-II consist of scales from 0 to 10 and use health assessment questionnaires to determine disease severity; they do not utilize affected joint counts or laboratory results. A score of 0.25 or less indicates remission. Low-severity disease is represented by a score of 0.26 to 3.7, and moderate disease activity is indicated by a score of 3.71 to less than 8. Severe disease activity is indicated by a score of 8 to 10.(73) [D in Context Link 1]

[E] The Routine Assessment of Patient Index Data 3 is a scale from 0 to 30 that is commonly used in clinical practice and uses a health assessment questionnaire and a patient global score to determine disease severity; it does not require joint counts or laboratory results. A score of 3 or less indicates remission. Low-severity disease is represented by a score of 4 to 6, and moderate disease activity is indicated by a score of 7 to 12. Severe disease activity is indicated by a score of 13 or greater.(73) [E in Context Link 1]

[F] The Simplified Disease Activity Index is a scale from 0 to 86 and is calculated by counting affected joints, the patient and provider global score, and the C-reactive protein level. A score of 3.3 or less indicates remission, while a score greater than 3.3 to 11 indicates low disease activity. Moderate disease activity is indicated by a score greater than 11 to 26, and severe disease activity is indicated by a score higher than 26.(73) [F in Context Link 1]

[G] Patients should be brought up to date on all vaccines prior to administration of abatacept.(1) [G in Context Link 1]

Codes

HCPCS: J0129

MCG Health
Ambulatory Care 30th Edition
Copyright © 2026 MCG Health, LLC
All Rights Reserved

Last Update: 1/25/2026 2:37:05 AM
Build Number: 30.0.2026012500524.025256